US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRO Concept

1,624.88

+53.413.40%

Number of Gainers:2

Number of Losers:- -

Number of Flat:1

PE:- -

High:1,628.55

Open:1,576.75

Low:1,557.22

Close:1,571.47

Loading ...

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

IQVIA Gains From Diversified Client Base Despite Low Liquidity Woes

ICON Public Limited Company (ICLR): A Bull Case Theory

New Tengah and Seletar MRT lines being studied, could be operational from 2040s

BRIEF-Iqvia Laboratories Launches Site Lab Navigator With Breakthrough E-Requisition Innovation To Transform Clinical Trials

IQVIA Laboratories Launches Site Lab Navigator With Breakthrough E-Requisition Innovation to Transform Clinical Trials

THOMSON REUTERS

IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials

Charles River Laboratories International Inc : Citigroup Raises Target Price to $175 From $155

THOMSON REUTERS

Charles River upgraded to Neutral from Sell at Citi

Charles River upgraded to Neutral from Sell at Redburn Atlantic

Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025

IQVIA Holdings (NYSE:IQV) Seems To Use Debt Quite Sensibly

Simply Wall St.

Fibrobiologics and Charles River Announce Completion and Release of Cywc628 Master Cell Bank for the Manufacturing of Fibroblast Cell-Based Wound Healing Therapeutic

THOMSON REUTERS

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy?

Charles River announces CAR T-cells agreement with Singapore General Hospital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4530/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4530"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4530\",,,,,undefined,":{"symbol":"BK4530","market":"US","secType":"PLATE","nameCN":"CRO Concept","latestPrice":1624.8768,"timestamp":1741381199999,"preClose":1571.4663,"halted":0,"volume":3140933,"delay":0,"changeRate":0.033988,"change":53.410522,"pbRate":4.34044,"amount":577425221.666218,"amplitude":0.045393,"prevYearClose":1673.3123,"fiveDayClose":1585.4698,"twentyDayClose":1728.141,"turnoverRate":0.014176,"marketCap":42784083968,"floatMarketCap":41665801216,"peRate":29.642919},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4530\",,,,,undefined,":{"symbol":"BK4530","high":1628.5504,"amplitude":0.045393,"preClose":1571.4663,"low":1557.2172,"pbRate":"4.34044","latestPrice":1624.8768,"volume":3140933,"delay":0,"open":1576.7549,"prevYearClose":1673.3123,"prevWeekClose":1585.4698,"prevMonthClose":1585.4698,"prevQuarterClose":1673.3123,"fiveDayClose":1585.4698,"twentyDayClose":1728.141,"sixtyDayClose":1709.6746,"secType":"PLATE","market":"US","turnoverRate":0.014176,"peRate":29.642919,"marketCap":42784083968,"floatMarketCap":41665801216,"timestamp":1741381199999,"nameCN":"CRO Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4530\",,,,undefined,":{"bkCode":"BK4530","up":2,"down":0,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4530\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517461615","title":"Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2517461615","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517461615?lang=en_us&edition=fundamental","pubTime":"2025-03-08 05:01","pubTimestamp":1741381260,"startTime":"0","endTime":"0","summary":"Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO BLA resubmission in the U.S.Atara remains focused on delivering on the future financial value of EBVALLO and has paused ATA3219 and ATA3431 CAR-T programs and implemented a workforce reduction of approximately 50% to preserve resources. \"We will further narrow our focus on the future financial value of EBVALLO for the benefit of all stakeholders. Atara continues to productively engage with our partner Pierre Fabre Laboratories and the FDA to help the third-party manufacturer adequately address the GMP compliance issues as we continue to work toward an expeditious path to release the clinical hold and resubmit the EBVALLO BLA,\" said Cokey Nguyen, President and Chief Executive Officer of Atara. \"With the focus on future EBVALLO value paramount, the Company has made the difficult decision to pause development of its allogeneic CAR-T cell programs and to discontinue all CAR-T operations includi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atara-biotherapeutics-announces-fourth-quarter-210100019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","PRGS","LU2065732104.USD","LU0390134368.USD","CRL","BK4530","BK4588","ATRA","BK4097","BK4121","BK4139"],"gpt_icon":0},{"id":"2517451786","title":"IQVIA Gains From Diversified Client Base Despite Low Liquidity Woes","url":"https://stock-news.laohu8.com/highlight/detail?id=2517451786","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517451786?lang=en_us&edition=fundamental","pubTime":"2025-03-08 00:33","pubTimestamp":1741365180,"startTime":"0","endTime":"0","summary":"IQVIA Holdings Inc. IQV is gaining from a massive addressable market, providing it with the opportunity to expand. An expansive database makes the company stand out from the herd and bars new entrants. However, no plan to pay dividends is often a red flag for dividend-seeking investors. A weak liquidity position adds to the concern.IQV reported impressive fourth-quarter 2024 results. Adjusted earnings were $3.12 per share, outpacing the Zacks Consensus Estimate marginally and rising 9.9% on a year-over-year basis. Total revenues of $4 billion surpassed the consensus estimate by a slight margin and grew 2.3% from the year-ago quarter.The company’s addressable market size surpassed the $330-billion mark and consists of outsourced research and development, real-world evidence and connected health, and technology-enabled clinical and commercial operations markets. The company aspires to expand and penetrate these markets by innovating and upgrading its offerings using its data, advanced an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/iqvia-gains-diversified-client-despite-163300575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IQV","LU0477156953.USD","LU0130103400.USD","LU1791710400.SGD","LU0980610538.SGD","LU0130518102.USD","BK4120","LU0648001328.SGD","BK4121","LU1791710582.SGD","LU0130517989.USD","LU1989764664.SGD","LU1989764748.USD","BK4588","LU0882574055.USD","BK4613","LU0198837287.USD","LU0477156797.USD","LU1201861249.SGD","BK4608","LU0648000940.SGD","BK4539","APP","ABM","BK4023","BK4585","BK4530","LU0130102774.USD","LU1201861165.SGD","LU1261432733.SGD","LU0528227936.USD"],"gpt_icon":0},{"id":"2517112272","title":"ICON Public Limited Company (ICLR): A Bull Case Theory","url":"https://stock-news.laohu8.com/highlight/detail?id=2517112272","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517112272?lang=en_us&edition=fundamental","pubTime":"2025-03-07 07:37","pubTimestamp":1741304240,"startTime":"0","endTime":"0","summary":"We came across abullish thesison ICON Public Limited Company  on Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on ICLR. ICON Public Limited Company 's share was trading at $186.49 as of March 5th. ICLR’s trailing and forward P/E were 19.57 and 13.21 respectively according to Yahoo Finance.ICON Public Limited Company  is not on our list of the30 Most Popular Stocks Among Hedge Funds. As per our database, 46 hedge fund portfolios held ICLR at the end of the fourth quarter which was 48 in the previous quarter. While we acknowledge the risk and potential of ICLR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ICLR but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.Disclosure: None. This article was originally published at In","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/icon-public-limited-company-iclr-233720294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1989764664.SGD","ICLR","LU0289960550.SGD","LU1043141123.HKD","LU0511384066.AUD","LU2244417387.USD","LU0130103400.USD","LU0477156797.USD","LU1989764748.USD","LU0426417589.USD","BK4021","LU0029864427.USD","LU1983260115.SGD","LU1043141396.HKD","LU0472753341.HKD","LU0310800379.SGD","LU1201861249.SGD","MEDP","LU2362540622.SGD","LU0477156953.USD","LU2065171402.SGD","LU0882574055.USD","BK4121","LU1267930813.SGD","LU0648001328.SGD","LU0114720955.EUR","LU2065171311.SGD","LU0994945656.USD","LU2324357040.USD","ICON","LU0187121727.USD","LU0426412945.USD","LU2362541513.USD","LU1791710582.SGD","LU0289961442.SGD","LU1201861165.SGD","LU0130102774.USD","LU0198837287.USD","LU0130518102.USD","LU2265009873.SGD","LU0128525929.USD","LU1261432733.SGD","LU1267930573.SGD","LU0069063385.USD","LU2065169927.USD","IQV","LU0889566641.SGD","BK4588","LU0708994859.HKD","BK4530"],"gpt_icon":0},{"id":"2517996210","title":"New Tengah and Seletar MRT lines being studied, could be operational from 2040s","url":"https://stock-news.laohu8.com/highlight/detail?id=2517996210","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517996210?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:39","pubTimestamp":1741160340,"startTime":"0","endTime":"0","summary":"The two new MRT lines could connect at Greater Southern Waterfront, according to preliminary assessments. ","market":"sg","thumbnail":"https://dam.mediacorp.sg/image/upload/s--JxfC_tXF--/c_crop,h_900,w_1600,x_0,y_110/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:cna,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2025/01/22/lan_1188.jpg?itok=WrbHBXva","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--JxfC_tXF--/c_crop,h_900,w_1600,x_0,y_110/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:cna,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2025/01/22/lan_1188.jpg?itok=WrbHBXva"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/new-mrt-lines-tengah-seletar-transport-4977621","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["BK4121","BK4585","BK4547","BK4588","LU0390134368.USD","CRL","BK4142","CCL","BK4230","BK4530","MRT","BK4517"],"gpt_icon":0},{"id":"2516000671","title":"BRIEF-Iqvia Laboratories Launches Site Lab Navigator With Breakthrough E-Requisition Innovation To Transform Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2516000671","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516000671?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:04","pubTimestamp":1741097043,"startTime":"0","endTime":"0","summary":"BRIEF-Iqvia Laboratories Launches Site Lab Navigator With Breakthrough E-Requisition Innovation To Transform Clinical TrialsMarch 4 (Reuters) - IQVIA Holdings Inc IQV.N:IQVIA LABORATORIES LAUNCHES SIT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA8Z34KD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791710582.SGD","LU1261432733.SGD","LU0882574055.USD","BK4530","LU0648001328.SGD","LU0130103400.USD","LU1791710400.SGD","LU0198837287.USD","IQV","LU1201861165.SGD","LU1989764748.USD","LU0980610538.SGD","BK4588","LU0130518102.USD","BK4121","LU0477156797.USD","LU0130517989.USD","LU0528227936.USD","BK4585","LU1201861249.SGD","LU1989764664.SGD","LU0130102774.USD","LU0648000940.SGD","LU0477156953.USD"],"gpt_icon":0},{"id":"2516671195","title":"IQVIA Laboratories Launches Site Lab Navigator With Breakthrough E-Requisition Innovation to Transform Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2516671195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516671195?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA8Z34KD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0198837287.USD","BK4530","LU1989764664.SGD","IQV","LU0130518102.USD","LU1201861165.SGD","BK4588","BK4121","LU0130103400.USD","LU0648000940.SGD","LU1261432733.SGD","LU1989764748.USD","LU1791710582.SGD","LU1791710400.SGD","LU0130517989.USD","LU0882574055.USD","LU1201861249.SGD","LU0528227936.USD","LU0477156953.USD","LU0980610538.SGD","LU0648001328.SGD","LU0130102774.USD","BK4585","LU0477156797.USD"],"gpt_icon":0},{"id":"2516674753","title":"IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674753","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674753?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., March 04, 2025----IQVIA Laboratories, a leading global drug discovery and development laboratory services organization, announces the launch of Site Lab Navigator, an advanced suite of solutions that automates and streamlines lab workflows for clinical trial sponsors and investigator sites.At the core of Site Lab Navigator is a new, innovative e-Requisition solution, which allows investigator sites to submit requisitions and manage lab specimens electronically, eliminating the need for manual, paper-based processes. This reduces administrative burden, minimizes errors, drives compliance and improves study execution for both sponsors and investigator sites.IQVIA Laboratories’ e-Requisition solution within the Site Lab Navigator suite of applications is a unique technology solution that offers capabilities unmatched by other requisitioning solutions available:. Seamless portal integration: Easy access via IQVIA’s One Home for Sites single sign-on.About IQVIA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/iqvia-laboratories-launches-lab-navigator-140000614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1261432733.SGD","LU0980610538.SGD","LU0477156953.USD","IQV","LU0130103400.USD","LU0130102774.USD","LU1791710400.SGD","LU0198837287.USD","LU0648001328.SGD","LU0648000940.SGD","NVGS","LU0130518102.USD","LU1989764748.USD","LU1791710582.SGD","BK4530","LU0528227936.USD","BK4144","LU1201861249.SGD","LU0882574055.USD","LU0130517989.USD","LU1989764664.SGD","BK4585","BK4588","BK4121","LU1201861165.SGD","LU0477156797.USD"],"gpt_icon":0},{"id":"2516458622","title":"Charles River Laboratories International Inc : Citigroup Raises Target Price to $175 From $155","url":"https://stock-news.laohu8.com/highlight/detail?id=2516458622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516458622?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:26","pubTimestamp":1741087588,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4530","BK4588","LU0390134368.USD","CRL","BK4585"],"gpt_icon":0},{"id":"2516629415","title":"Charles River upgraded to Neutral from Sell at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2516629415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516629415?lang=en_us&edition=fundamental","pubTime":"2025-03-04 18:16","pubTimestamp":1741083365,"startTime":"0","endTime":"0","summary":"Citi analyst Patrick Donnelly upgraded Charles River (CRL) to Neutral from Sell with a price target of $175, up from $155. The firm thinks headwind...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/charles-river-upgraded-to-neutral-from-sell-at-citi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/charles-river-upgraded-to-neutral-from-sell-at-citi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4530","BK4588","BK4121","CRL","BK4585","LU0390134368.USD"],"gpt_icon":0},{"id":"2516668186","title":"Charles River upgraded to Neutral from Sell at Redburn Atlantic","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668186","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516668186?lang=en_us&edition=fundamental","pubTime":"2025-03-03 18:35","pubTimestamp":1740998154,"startTime":"0","endTime":"0","summary":"Redburn Atlantic upgraded Charles River (CRL) to Neutral from Sell with an $188 price target The firm says demand in the company’s Discovery and Sa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/charles-river-upgraded-to-neutral-from-sell-at-redburn-atlantic?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/charles-river-upgraded-to-neutral-from-sell-at-redburn-atlantic?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0390134368.USD","BK4530","BK4585","CRL","BK4588","BK4121"],"gpt_icon":0},{"id":"2516569505","title":"Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516569505","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516569505?lang=en_us&edition=fundamental","pubTime":"2025-03-02 04:19","pubTimestamp":1740860399,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025.In this article, we are going to take a look at where Sage Therapeutics, Inc.  stands against the other psychedelic stocks.The Therapeutic Potential and Investment Boom in Psychedelic Medicine. Psilocybin  is the most widely used psychedelic drug in the United States, with an estimated 8 million American adults using it in 2023, according to a survey conducted by RAND Corporation. Around 12% of respondents reported lifetime use, and 3.1% used it in the past year. LSD use has also risen significantly, particularly among individuals aged 18-25, with usage increasing from 0.9% in 2002 to 4% in 2019. The LSD market is projected to grow from $145.9 million in 2024 to $265.7 million by 2034. MDMA, although not providing specific usage data, remains popular, especially in research for PTSD treatment. Ketamine has gained attention for its depression","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-therapeutics-inc-sage-among-201959349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","PPD","SAGE","MNQmain","QLD","TSYW.SI","USJW.SI","TQQQ","NVIW.SI","NQmain","SQQQ","BK4561","BK4139","BK4121","BK4530","USAW.SI","QID",".IXIC"],"gpt_icon":1},{"id":"2514613325","title":"IQVIA Holdings (NYSE:IQV) Seems To Use Debt Quite Sensibly","url":"https://stock-news.laohu8.com/highlight/detail?id=2514613325","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514613325?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744016,"startTime":"0","endTime":"0","summary":"Legendary fund manager Li Lu  once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. As with many other companies IQVIA Holdings Inc.  makes use of debt. But the more important question is: how much risk is that debt creating?IQVIA Holdings has a debt to EBITDA ratio of 4.2 and its EBIT covered its interest expense 3.7 times. This suggests that while the debt levels are significant, we'd stop short of calling them problematic. On a slightly more positive note, IQVIA Holdings grew its EBIT at 10% over the last year, further increasing its ability to manage debt. The balance sheet is clearly the area to focus on when","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/iqvia-holdings-nyse-iqv-seems-120016504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EBIT","LU0130102774.USD","LU0130517989.USD","LU0528227936.USD","LU0882574055.USD","LU0198837287.USD","BK4585","LU0648000940.SGD","LU0130103400.USD","LU0130518102.USD","LU1791710400.SGD","LU0477156797.USD","LU1791710582.SGD","LU0477156953.USD","BK4530","IQV","LU0648001328.SGD","BK4588","LU1261432733.SGD","LU1201861249.SGD","LU1989764664.SGD","LU1989764748.USD","LU0980610538.SGD","LU1201861165.SGD","NYSE","BK4121"],"gpt_icon":0},{"id":"2514980244","title":"Fibrobiologics and Charles River Announce Completion and Release of Cywc628 Master Cell Bank for the Manufacturing of Fibroblast Cell-Based Wound Healing Therapeutic","url":"https://stock-news.laohu8.com/highlight/detail?id=2514980244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514980244?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:30","pubTimestamp":1740663007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI1BV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4121","BK4530","LU0390134368.USD","BK4585","BK4139","CRL","FBLG"],"gpt_icon":0},{"id":"2514780569","title":"GH Research Reports Full Year 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514780569","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514780569?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025. Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK. Full response to the IND hold on track for submission in mid-2025. Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024. Net cash proceeds of an additional $139.8 million from public offering received in February 2025. DUBLIN, Feb. 27, 2025  -- GH Research PLC , a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2024, and provided updates on its business.As previously announced, our Investigational New Drug Application  for GH001 administered using our proprietary aerosol delivery device","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gh-research-reports-full-2024-120000403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GH","BK4551","BK4585","BK4535","BK4561","BK4539","GHRS","PPD","BK4196","BK4121","BK4007","BK4588","BK4530"],"gpt_icon":0},{"id":"2514114490","title":"IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514114490","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514114490?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:40","pubTimestamp":1740494411,"startTime":"0","endTime":"0","summary":"It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.Why Investors Should Pay Attention to This Value Stock. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.IQVIA Holdings Inc.  : Free Stock Analysis Report. This article originally published on Za","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/iqvia-holdings-iqv-top-ranked-144011761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU0477156953.USD","LU1989764748.USD","LU0882574055.USD","LU0648001328.SGD","LU0980610538.SGD","LU0198837287.USD","LU0477156797.USD","LU0130103400.USD","LU0130517989.USD","LU0130518102.USD","BK4530","IQV","LU1791710400.SGD","LU1261432733.SGD","LU1989764664.SGD","LU0130102774.USD","BK4588","LU0528227936.USD","LU1201861249.SGD","LU1201861165.SGD","LU0648000940.SGD","BK4121","LU1791710582.SGD"],"gpt_icon":0},{"id":"2514091534","title":"Charles River announces CAR T-cells agreement with Singapore General Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=2514091534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514091534?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:15","pubTimestamp":1740489339,"startTime":"0","endTime":"0","summary":"Charles River (CRL) Laboratories International announced an agreement with Singapore General Hospital SGH to provide Current Good Manufacturing Pra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/charles-river-announces-car-t-cells-agreement-with-singapore-general-hospital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/charles-river-announces-car-t-cells-agreement-with-singapore-general-hospital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRL","BK4530","BK4121","BK4585","BK4230","LU0390134368.USD","BK4588","BK4022","CAR"],"gpt_icon":0}],"pageSize":16,"totalPage":2,"pageCount":1,"totalSize":26}]}}